Endocrine/metabolicLiver-targeted ASO tackles early MASLDResearchers from Yunnan University, Sicagene Bioscience Co. Ltd. and collaborators reported the preclinical efficacy of GS-10c, a GalNAc-conjugated antisense oligonucleotide (ASO) developed to silence serine/threonine kinase 25 (STK25), a lipid droplet-associated kinase implicated in the development of metabolic dysfunction-associated steatotic liver disease (MASLD).